Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCAGN02390 (Verzistobart) in advanced malignancies
NCT03652077Phase 1Completed
- Sponsor
- Incyte
- Start
- Sep 2018
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of verzistobart in Cervical Cancer (CC), gastric cancer (GC), gastroesophageal junction cancer and 13 more, sponsored by Incyte. Primary endpoints: Number of treatment-emergent adverse events up to 12 months and Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390. Started Sep 2018; status: completed.
02
Drugs
verzistobart
03
Conditions
Cervical Cancer (CC)gastric cancer (GC)gastroesophageal junction canceresophageal cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03652077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652077.